TM008 Clinical Trial

Huddle presentation

A Phase 2b, Double-blind, Randomized, Placebo-controlled, Dose-finding, Multi-center, 36-week Safety and Efficacy Study with Open-label Extension Period of Tesomet in Subjects with Hypothalamic Obesity.

See if you qualify now, or copy the link and send to someone you know!

    See If You Qualify